Clinical trial NCT06721962: Treatment of Moderate to Severe Refractory Crohn's Disease
Official title: A Phase 1/2a, Open Label, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of TRX103 in Subjects With Moderate to Severe Treatment-Refractory Crohn's Disease
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Crohns Disease
Keywords: Tr1X
RESTORE
Crohns
Crohns Disease
autoimmune
IBD
CD
chronic inflammation
gastrointestinal tract
chronic diarrhea
intestinal ulcers
abdominal pain
Lead sponsor: Tr1X, Inc.
Sponsor class: INDUSTRY
First posted: 2024-12-06
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn's Disease (CD). The primary purpose of this study is to learn how safe and effective different doses of TRX103 are when administered to individuals with CD.

Detailed description: Please see our study website at https://www.cdclinicaltrial.com

Eligibility criteria: Inclusion Criteria:

1. Male and females ≥ 18 and ≤ 65 years of age at time of Screening
2. Weight of ≥ 40 kg
3. Medical history and biological evidence of active bowel inflammation documented by:

   * Minimum of approximate 1 year of Crohn's disease diagnosis confirmed through Endoscopy, and;
   * Endoscopic evidence of CD diagnosis at least 3 months prior to and/or at Screening (SES-CD ≥ 6 by central reader), and;
   * Highly sensitive C-reactive protein (hs-CRP) \> 5 mg/L at Screening.
4. Active disease defined as moderate to severe active CD at Screening defined by all of the following:

   * Evidence of mucosal inflammation, defined as SES-CD ≥ 6 (≥ 4 for subjects with isolated ileal disease), and;
   * Average daily very soft or liquid stool frequency (SF) ≥ 4 and/or average daily abdominal pain (AP) score ≥ 2 (values represent the unweighted daily averages of the corresponding sub-scores from the CDAI and total scores

     * 220).
5. Subject on treatment with corticosteroids may be included if they meet the following:

   * prednisone or equivalent dose ≤ 20 mg/day; or
   * budesonide ≤ 9 mg/day; or
   * has been on a stable dose for at least 7 days prior to TRX103 dose.
6. Advanced therapy-refractory disease defined by:

   * Failure of two or more advanced approved therapies. Prior therapies may be inclusive of any combination of the following:
   * TNF-alpha inhibitors
   * IL-12/23 inhibitors
   * Anti-integrins
   * JAK inhibitors
   * OR
   * Non-response (primary failure), complete loss of response (secondary failure) or intolerant to therapy at a dose indicated for CD.
7. Absence of uncontrolled bacterial, viral, or fungal infection at time of enrollment.
8. Subjects must be able to understand and sign informed consent and be willing and able to complete all specified procedures and visits.

Exclusion Criteria:

1. Prior organ transplant, or allogeneic bone marrow, peripheral blood, or cord blood stem cell transplant.
2. Received another investigational agent or therapy, within 28 days of planned TRX103 infusion (or 5 half-lives, whichever is longer) and/or have not recovered from treatment related toxicities.
3. Received any approved treatment for CD within the designated washout period (including off-label use of approved therapies) as per the protocol (see Table 4).
4. Strictures, active fistulae (including perianal), or abscess by computed tomography (CT) or magnetic resonance enterography (MRE) or Endoscopy within 6 months of Screening.
5. Positive serology for HIV.
6. Positive hepatitis-B surface antigen. Subject may be included if they are HBV PCR negative.
7. Hepatitis C virus (HCV RNA detectable in any subject with anti-HCV antibodies).
8. Subject with active or chronic recurring infections or untreated latent Tuberculosis (TB).
9. Current diagnosis of ulcerative colitis (UC), indeterminate colitis or CD isolated to colon only (the colitis must be related to CD and inclusive of ileal with or without colonic involvement).
10. Subjects with the following known complications of Crohn's Disease

    * active diverticulitis,
    * active fistulae or abscess,
    * abscess (abdominal or perianal),
    * impassable fibrotic strictures,
    * symptomatic bowel strictures,
    * fulminant colitis,
    * toxic megacolon,
    * ostomy or ileoanal pouch,
    * diagnosed with short gut or short bowel syndrome,
    * or any other manifestation that might require surgery while enrolled in the study.
11. Subject with surgical bowel resection within the past 3 months prior to Screening, or a history of \> 2 bowel resections.
12. Subjects that are pregnant, breast feeding, or aim to become pregnant during the 12 month study period. (Subjects, males and females, must agree to use a highly effective method of contraception).
13. Screening laboratory and other analyses show any of the following abnormal results:

    * Serum aspartate transaminase or alanine transaminase \> 3.0 × upper limit of normal;
    * Total white blood cell count \< 2,000/μL;
    * Estimated glomerular filtration rate by simplified 4-variable Modification of Diet in Renal Disease (MDRD) formula \< 40 mL/min/1.73 m2;
    * Hemoglobin \< 8 g/dL;
    * Bilirubin ≥ 2 x ULN;
    * Platelet count \< 100,000/μL;
    * Absolute neutrophil count \< 1,200/μL;
    * Absolute lymphocytes count \< 750/μL.
14. Any subject with a history of significant renal, hepatic, pulmonary, or cardiac dysfunction, or on treatment to support cardiac dysfunction.
15. Any serious illness, uncontrolled inter-current illness, psychiatric illness, active or uncontrolled infection, or other medical condition or history, including laboratory results, which, in the Investigator's opinion:

    * places the subject at increased risk during participation in the study, and/or;
    * interferes with the subject's capacity to provide informed consent and their participation in the study, and/or;
    * interferes with the interpretation of the results.

Primary outcomes:
measure: To assess the safety and tolerability of TRX103 infusion in subjects with moderate to severe treatment-refractory Crohn's Disease.
timeFrame: From baseline until 12 months post TRX103 infusion.
Secondary outcomes:
measure: Improvement in Simple Endoscopic Score for Crohn's Disease (SES-CD Score).
timeFrame: From baseline to Week 12 post TRX103 infusion.
measure: Improvement of CD status.
timeFrame: From baseline to Week 12 post TRX103 infusion.
measure: Reduction in Fecal Calprotectin.
timeFrame: From baseline to Week 12 post TRX103 infusion.
measure: Reduction of highly sensitive C-reactive protein (hs-CRP).
timeFrame: From baseline until 12 months post TRX103 infusion.
measure: Improvement in Patient Reported Outcomes (PRO).
timeFrame: From baseline until 12 months post TRX103 infusion.
measure: Pharmacokinetics (PK) of TRX103.
timeFrame: From baseline until 12 months post TRX103 infusion.
measure: Level of Inflammation and mucosal damage
timeFrame: From baseline until 12 months post TRX103 infusion.
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: University of California, San Francisco
state: California
city: Tampa
country: United States
facility: University of South Florida
state: Florida
city: Chicago
country: United States
facility: University of Chicago
state: Illinois
city: Iowa City
country: United States
facility: University of Iowa
state: Iowa
city: Ann Arbor
country: United States
facility: University of Michigan, Ann Arbor
state: Michigan
city: St. Louis
country: United States
facility: Washington University in St. Louis
state: Missouri
city: Cleveland
country: United States
facility: Cleveland Clinic
state: Ohio
Study officials:
References: